文献速递淋巴瘤

匹妥布替尼在中国CLL/SLL患者中的BRUIN CLL-321三期研究分析

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
PubMed 文献 · Br J Haematol · 2026-01-22

BRUIN CLL-321是首个在共价BTK抑制剂经治的CLL/SLL患者中开展的前瞻性随机研究。本报告呈现中国患者亚组结果:40例患者随机接受匹妥布替尼或BendaR,IRC评估的中位PFS分别为未达到和10.6个月(分层HR=0.281,95%CI 0.070-1.125,名义p=0.0554),安全谱更优。

要点

  • 匹妥布替尼组IRC评估中位PFS未达到,BendaR组为10.6个月,HR=0.281。
  • 匹妥布替尼组≥3级TEAE发生率36.8%,BendaR组93.3%。
  • 中国患者亚组结果支持匹妥布替尼作为cBTKi经治CLL/SLL的可选方案。

核心结论

  • 在中国cBTKi经治的CLL/SLL患者中,匹妥布替尼显示出临床活性和可耐受的安全性。

研究设计与样本

  • BRUIN CLL-321为前瞻性随机研究,中国患者按1:1随机接受匹妥布替尼200 mg每日一次或研究者选择的BendaR。
  • 中国患者共40例,匹妥布替尼组19例,BendaR组21例。

主要发现

  • IRC评估中位PFS:匹妥布替尼组未达到,BendaR组10.6个月(分层HR=0.281,95%CI 0.070-1.125,名义p=0.0554)。
  • TTNT:HR=0.150(95%CI 0.031-0.728);EFS:HR=0.322(95%CI 0.094-1.101)。
  • OS趋势:HR=0.343(95%CI 0.031-3.787)。
  • 安全性:≥3级TEAE发生率36.8% vs 93.3%,严重不良事件发生率15.8% vs 46.7%。

临床怎么用

  • 对于cBTKi经治的中国CLL/SLL患者,匹妥布替尼可作为临床活性且耐受性良好的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRUIN CLL-321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression-free survival (PFS) compared to investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BendaR). This report presents results from Chinese patients enrolled in BRUIN CLL-321, who were randomized 1:1 to pirtobrutinib (200 mg once daily) or IC of BendaR (idelalisib is not approved in China). End-points included independent review committee (IRC)-assessed PFS, investigator (INV)-assessed PFS, overall survival (OS), event-free survival (EFS), time to next treatment (TTNT) and safety. Among 40 Chinese patients (pirtobrutinib n = 19; BendaR n = 21), IRC-assessed PFS favoured pirtobrutinib (stratified hazard ratio [HR] = 0.281; 95% confidence interval [CI], 0.070-1.125, nominal p = 0.0554), with median PFS not reached versus 10.6 months with BendaR; INV-assessed PFS supported these findings. TTNT (HR = 0.150; 95% CI, 0.031-0.728) and EFS (HR = 0.322; 95% CI, 0.094-1.101) were also improved. A trend towards OS benefit was observed (HR = 0.343; 95% CI, 0.031-3.787). Pirtobrutinib showed a favourable safety profile, with fewer grade ≥3 treatment-emergent adverse events (36.8% vs. 93.3%) and serious adverse events (15.8% vs. 46.7%). These findings support pirtobrutinib as a clinically active and tolerable option for cBTKi-pretreated Chinese CLL/SLL population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yi S, Cao J, Feng R, et al. A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321. Br J Haematol. 2026. PMID: 41571607. doi:10.1111/bjh.70334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。